These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16608668)

  • 1. Trouble at the FDA: can we fix the problems affecting you and your patients?
    Henley E
    J Fam Pract; 2006 Apr; 55(4):301-4. PubMed ID: 16608668
    [No Abstract]   [Full Text] [Related]  

  • 2. Should you let the FDA decide what drugs you pay for?
    Dutton G
    Bus Health; 1996 Oct; 14(10):65, 69-70, 73. PubMed ID: 10161492
    [No Abstract]   [Full Text] [Related]  

  • 3. Protecting the health of the public--Institute of Medicine recommendations on drug safety.
    Psaty BM; Burke SP
    N Engl J Med; 2006 Oct; 355(17):1753-5. PubMed ID: 17030843
    [No Abstract]   [Full Text] [Related]  

  • 4. Change, but not in dollar bills. FDA needs more than money to fix problems: Congress.
    Lubell J
    Mod Healthc; 2008 Feb; 38(5):10-1. PubMed ID: 18320666
    [No Abstract]   [Full Text] [Related]  

  • 5. What ails the FDA?
    Jenny-Avital ER
    N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract]   [Full Text] [Related]  

  • 6. Making a difference.
    Nat Biotechnol; 2009 Apr; 27(4):297. PubMed ID: 19352347
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA likely to further restrict erythropoietin use for cancer patients.
    Fox JL
    Nat Biotechnol; 2007 Jun; 25(6):607-8. PubMed ID: 17557084
    [No Abstract]   [Full Text] [Related]  

  • 8. Vioxx, radiology, and the Food and Drug Administration.
    Pentecost MJ
    J Am Coll Radiol; 2005 May; 2(5):394-7. PubMed ID: 17411841
    [No Abstract]   [Full Text] [Related]  

  • 9. Perspectives. Approval process a moving target in FDA reform hearings.
    Rhein R
    Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
    [No Abstract]   [Full Text] [Related]  

  • 10. [FDA's new drug approval system].
    Ishii A
    Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565
    [No Abstract]   [Full Text] [Related]  

  • 11. The drive to reform the FDA gains momentum.
    Gatty B
    Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
    [No Abstract]   [Full Text] [Related]  

  • 12. Who would approve new drugs if there were no FDA?
    Gatty B
    Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory science as culture: contested two-dimensional values at the US FDA.
    Abraham J
    Sci Cult (Lond); 2002 Sep; 11(3):309-35. PubMed ID: 15971364
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 15. Withdrawals of FDA-approved drugs raise questions.
    Mayo Clin Health Lett; 1998 Nov; 16(11):4. PubMed ID: 9809019
    [No Abstract]   [Full Text] [Related]  

  • 16. Blueprint for a stronger Food and Drug Administration.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2006 Oct; 355(17):1821. PubMed ID: 17030844
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA embraces risk-management approach.
    Fox JL
    Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA appointee faces angry, demoralized staff.
    Fox JL
    Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.